Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Arcadia Biosciences's Debt-to-EBITDA or its related term are showing as below:
RKDA's Debt-to-EBITDA is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 2.12 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Arcadia Biosciences Debt-to-EBITDA Related Terms
Arcadia Biosciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Arcadia Biosciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RKDA vs ORISF, ARRT, CIMG: Debt-to-EBITDA Comparison
For the Packaged Foods subindustry, Arcadia Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcadia Biosciences Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Arcadia Biosciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Arcadia Biosciences (RKDA) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Arcadia Biosciences. According to the industry distribution chart, Arcadia Biosciences ranks #999999 out of 1554 companies in the Consumer Packaged Goods industry.
Is Arcadia Biosciences' Debt-to-EBITDA too high?
Arcadia Biosciences' current Debt-to-EBITDA is 0.00. Based on the distribution chart, Arcadia Biosciences ranks #999999 out of 1554 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Arcadia Biosciences has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arcadia Biosciences' Debt-to-EBITDA compare to ORISF and ARRT?
According to the Consumer Packaged Goods industry distribution chart, Arcadia Biosciences ranks #999999 out of 1554 companies for Debt-to-EBITDA. This places Arcadia Biosciences in the lower half of its industry. The industry median Debt-to-EBITDA is 2.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.12, based on 1,554 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Arcadia Biosciences. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcadia Biosciences's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcadia Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcadia Biosciences (RKDA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.84, compared to a current price of $0.56 — trading 80.3% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Arcadia Biosciences' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Arcadia Biosciences (RKDA), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcadia Biosciences (RKDA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcadia Biosciences stock appears to be undervalued.
The current stock price of $0.56 is trading 80.3% below its estimated GF Value™ of $2.84.
GuruFocus considers Arcadia Biosciences to be Possible Value Trap.
Key valuation signals for RKDA:
Debt-to-EBITDA: 0.00
GF Value™: $2.84 vs. price of $0.56 (80.3% below fair value)
No single metric tells the full story. See the RKDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
43GF Score
Get the complete analysis for RKDA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RKDA has been successfully added to your 
